StockTipsArenaBeta

BUY Granules India — IDBI Capital

BUYGranules India
Granules India share price target & all analyst calls

byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))7 Oct 2026via IDBI Capital Research Calls Telegram

Entry₹843Stated
Target₹878
Total upside +4.15% (call closed)
Stop loss₹826-2.02% risk
Exit₹8268 Oct 2026, 11:30 am
Stop-loss hit-2.02%
Follow IDBI Capital for new calls(26% target hit, 339 closed calls)Get alertsWatch GRANULES for new buy/sell callsGet alertsSee 195 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Oct, 7:54 pm IST
3 supporting0 opposing
Supports the BUY call (3)

Granules India has submitted a Paragraph IV certification for its ANDA for Ruxolitinib Extended-Release Tablets, potentially qualifying for first-to-file status and 180 days of generic exclusivity.

NSE · Press Release·7 Oct · today

(opens in new tab)

Granules India has submitted a Paragraph IV certification for its ANDA for Ruxolitinib Extended-Release Tablets, potentially qualifying for 180 days of generic drug exclusivity in the U.S. market.

BSE · Company Update·7 Oct · today

(opens in new tab)

Granules India incorporates wholly owned subsidiary in Brazil

NewsCnbc-Tv18·2 Oct · 5d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Granules India

All analyst calls on Granules India

More from IDBI Capital

Every call and its outcome